Acting” has been dropped from the titles of the interim directors of the U.S. FDA’s drug and biologics centers, with Michael Davis and Karim Mikhail officially appointed late Sept. 8 as the directors ...

Kura Oncology Inc. announced today that it has spun out Caspian Therapeutics Inc. to advance small-molecule menin inhibitors ...

AI imaging platforms are certainly transforming diagnosis and treatment of neurodegenerative diseases and helping to bring ...

Kyowa Kirin Co. Ltd. reported mixed phase II results for KHK-4951, a nanocrystal tivozanib eye drop being developed as a maintenance therapy for neovascular age-related macular degeneration (nAMD), ...

Pharvaris NV has added positive phase III clinical data in the prevention of hereditary angioedema (HAE) attacks to earlier ...

Amgen Inc.’s Imdelltra (tarlatamab), paired with Astrazeneca plc’s PD-L1 inhibitor Imfinzi (durvalumab), met the primary overall survival (OS) endpoint in a phase III study of first-line maintenance ...

Shares of Tyra Biosciences Inc. (NASDAQ:TYRA) were trading at $20.95, down $5.78, or 21%, on first results from Surf302, the phase II study evaluating dabogratinib in patients with fibroblast growth ...

Shares of Evommune Inc. (NASDAQ:EVMN) dropped 17% to close at $10.84 Sept. 9 after the firm reported disappointing top-line results from a phase IIb trial of EVO-756 in adults with moderate to severe ...

Aiming to “bend the curve toward longer disease-free survival” with improved safety in non-muscle-invasive bladder cancer (NMIBC), Tyra Biosciences Inc. CEO Todd Harris said the company has settled on ...

Andarta Therapeutics Pte Ltd. has obtained rights to advance Teva Pharmaceutical Industries Ltd.’s fatty acid synthase (FASN) inhibitor program for Parkinson’s disease.

CSPC Pharmaceutical Group Ltd.’s SYH-2083 eye drop preparation has received clinical trial approval from China’s National Medical Products Administration (NMPA) for dry eye disease.

Ltd. has received IND clearance from the FDA for AP-308, a first-in-class engineered recombinant IgA protease designed for the functional cure of IgA nephropathy (IgAN).